SCHEMBL662028

SCHEMBL662028

NNc1ccncc1C(N)=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT3 Q9NTG7 2/20 0.58
TDP1 Q9NUW8 2/20 0.58
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA9 Q16790 1/20 0.50
CA14 Q9ULX7 1/20 0.50
IRAK4 Q9NWZ3 1/20 0.48
KDM4E B2RXH2 4/20 0.44
HTT P42858 1/20 0.44
F7 P08709 1/20 0.42
F3 P13726 1/20 0.42
SARM1 Q6SZW1 1/20 0.42
SIRT2 Q8IXJ6 1/20 0.42
SIRT6 Q8N6T7 1/20 0.42
SIRT1 Q96EB6 1/20 0.42
SIRT5 Q9NXA8 1/20 0.42
SIRT4 Q9Y6E7 1/20 0.42
KDM4C Q9H3R0 3/20 0.42
ALDH1A1 P00352 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9142180 0.98 SIRT3 (0.56) SIRT3TDP1CA12CA1CA2
Hydrochloric Acid SCHEMBL7084808 0.98 SIRT3 (0.56) SIRT3TDP1CA12CA1CA2
Acetone SCHEMBL5667714 0.94 SIRT3 (0.58) SIRT3TDP1CA12CA1CA2
SCHEMBL6757557 0.88 SIRT3 (0.58) SIRT3TDP1IRAK4KDM4EHTT
SCHEMBL3569822 0.86 SIRT3 (0.61) SIRT3TDP1CA12CA1CA2
SCHEMBL19611328 0.84 KDM4C (0.55) SIRT3TDP1CA12CA1CA2
SCHEMBL188821 0.84 KDM4C (0.55) SIRT3TDP1CA12CA1CA2
SCHEMBL4654937 0.82 CA12 (0.49) SIRT3TDP1CA12CA1CA2
Cysteine SCHEMBL14333909 0.82 PTGS1 (0.43) SIRT3TDP1CA12CA1CA2
SCHEMBL30545160 0.80 SIRT3 (0.54) SIRT3TDP1IRAK4KDM4EKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1080 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260077073-A1 GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-TARGETED COMPOUNDS AND USES THEREOF ALPHA 9 ONCOLOGY INC (CA) 2026-03-19 US claimed
US-20250346589-A1 RADIOISOTOPE LABELED SSTR2-AGONISTS WITH LINKERS UNIV ERASMUS MED CT ROTTERDAM (NL) 2025-11-13 US claimed
US-20250295821-A1 TARGETED RADIOPHARMACEUTICAL FOR TUMOR AND ITS USE IN THE IMAGING-GUIDED COMBINATION THERAPY OF TARGETED RADIOTHERAPY AND IMMUNOTHERAPY BeijingGiluntidePharmaceuticalCo.,Ltd. (CN) 2025-09-25 US claimed
WO-2025147774-A1 COMPOSITIONS TARGETING BRADYKININ RECEPTOR B1 FOR MEDICAL IMAGING AND TREATMENT OF CANCER AND OTHER DISORDERS ALPHA-9 ONCOLOGY INC. (CA) 2025-07-17 WO claimed
WO-2025125621-A1 CANCER-ASSOCIATED PROTEIN-TARGETED STRONG OR COVALENTLY BINDING PRECURSOR COMPOUNDS AND RADIOTRACERS RADIOVAXX GMBH (DE) 2025-06-19 WO claimed
US-20250195702-A1 RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS PROVINCIAL HEALTH SERVICES AUTHORITY (CA) 2025-06-19 US claimed
CN-116370660-B PECAM-1 targeting diagnosis and treatment integrated nano-probe and preparation method and application thereof 华中科技大学同济医学院附属协和医院 2025-05-30 CN claimed
US-20250161501-A1 Radiolabeled Compounds for Imaging of Fibroblast Activation Protein (FAP) and Treatment of FAP-Related Disorders PROVINCIAL HEALTH SERVICES AUTHORITY (CA) 2025-05-22 US claimed
EP-4529474-A1 RADIOISOTOPE LABELED SSTR2-AGONISTS WITH LINKERS Erasmus University Rotterdam Medical Center (NL) 2025-04-02 EP claimed
EP-3965885-B1 METHODS AND COMPOSITIONS FOR REVERSING PLATELET CLUMPING TRUVIAN SCIENCES INC (US) 2025-03-26 EP claimed
EP-1208116-A2 SOMATOSTATIN ANALOGS, RADIOLABELLED DERIVATIVES THEREOF AND THEIR USE SCHERING AKTIENGESELLSCHAFT (DE) 2002-05-29 EP claimed
US-6358491-B1 FOR CANCER IMAGING AND THERAPY USING NOVEL SOMATOSTATIN ANALOGS, MEDICAL DIAGNOSIS, RADIOPHARMACEUTICALS BERLEX LABORATORIES, INC. 2002-03-19 US claimed
CN-1077439-C Labeled chemotactic peptides for imaging of sites of infection or inflammation lesions GEN HOSPITAL CORP (US) 2002-01-09 CN claimed
WO-2001060863-A1 RADIOLABELED VASOACTIVE INTESTINAL PEPTIDE ANALOGS FOR DIAGNOSIS AND RADIOTHERAPY DABUR RESEARCH FOUNDATION (IN) 2001-08-23 WO claimed
WO-2001044177-A2 SOMATOSTATIN ANALOGS, RADIOLABELLED DERIVATIVES THEREOF AND THEIR USE SCHERING AKTIENGESELLSCHAFT (DE) 2001-06-21 WO claimed
US-6197278-B1 IMAGING APOPTOSIS BY ADMINISTERING TO THE PATIENT, ANNEXIN LABELED WITH A RADIONUCLIDE, MEASURING RADIATION EMISSION FROM RADIONUCLIDE WITH RADIO DETECTOR TO CONSTUCT AN IMAGE OF RADIATION EMISSION WHICH REPRESENT CELL DEATH OF THE MAMMAL THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2001-03-06 US claimed
CN-1265572-A Method for imaging cell death in vivo UNIV LELAND STANFORD JUNIOR (US) 2000-09-06 CN claimed
EP-1017318-A1 METHOD OF IMAGING CELL DEATH IN VIVO THE BOARD OF DIRECTORS OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2000-07-12 EP claimed
WO-1998048699-A1 METHOD OF IMAGING CELL DEATH IN VIVO THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 1998-11-05 WO claimed
WO-1994028943-A1 ANALOGS OF CYTOCHALASIN B AS RADIOPHARMACEUTICALS FOR NUCLEAR IMAGING OF TRANS-MEMBRANE GLUCOSE TRANSPORT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1994-12-22 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346589-A1 RADIOISOTOPE LABELED SSTR2-AGONISTS WITH LINKERS SSTR2, SSTR5, SSTR1 SIRT3 1762/4885TDP1 4134/4885CA12 291/4885
US-20250295821-A1 TARGETED RADIOPHARMACEUTICAL FOR TUMOR AND ITS USE IN THE IMAGING-GUIDED COMBINATION THERAPY OF TARGETED RADIOTHERAPY AND IMMUNOTHERAPY CD274, ITGB1, ITGA1 SIRT3 1651/4885TDP1 2018/4885CA12 1222/4885
US-20250161501-A1 Radiolabeled Compounds for Imaging of Fibroblast Activation Protein (FAP) and Treatment of FAP-Related Disorders FAP, FIBP, FGFR1 SIRT3 3619/4885TDP1 2737/4885CA12 1026/4885
US-20250195702-A1 RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS GRPR, NPY5R, NPY2R SIRT3 2574/4885TDP1 923/4885CA12 930/4885
US-20260077073-A1 GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-TARGETED COMPOUNDS AND USES THEREOF GRPR, GIPR, GLP1R SIRT3 4186/4885TDP1 1563/4885CA12 663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.